

RutiSeton: Allowing In-Office Treatment of Anal Fistula Without General Anesthesia



OVERVIEW

RutiSeton is a novel medical device for treating anal fistulas which incorporates a flexible probe which enhances patient outcomes and comfort with a non-invasive approach, cutting costs and reducing hospital resource use by removing the need of an operation room and anesthesia.



PROJECT

Sector: Proctology, Anal Fistulas

R&D direction:

Developing non-invasive solutions for anal fistula treatment

Stage of development: TRL2-3

Scientific leader: Dr. Jose Troya



PRODUCT

Potential indications:

Anal Fistula

Mechanism of action:

Probe based on a new flexible material covered with a hidrofilic compound which removes need for anesthesia.

Market Size: €8B in 2023



IP PROTECTION

Patent filed



OPPORTUNITY

License out

Co-development



NEED

Anal fistulas affect approximately **1 in 10,000** individuals annually, often requiring costly and complex surgery, with **expenses up to \$10,000 per procedure** and significant recovery times. Traditional treatments can lead to high complication rates and extended hospital stays.



SOLUTION

RutiSeton meets this need by introducing a flexible probe that enables effective treatment of anal fistulas without the need for a surgical room or anesthesia. The device's design allows for precise placement and management of the fistula, enhancing the medical treatment process while maintaining patient comfort. Its minimally invasive nature allows streamlining patient care and reducing overall healthcare costs.



KEY ADVANTAGES

- ✓ Enhanced patient comfort: minimizes discomfort, eliminating the need for OR and anesthesia.
- ✓ Cost efficiency: reduces overall treatment costs by avoiding the use of a surgical room and anesthesia.
- ✓ Streamlined care: enables outpatient treatment, lowering hospital strain and resource use.

CONTACT US!

innovation@igtp.cat

Innovation & Business Development Unit

